More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$310768039
EPS
-2.42
P/E ratio
--
Price to sales
5.58
Dividend yield
--
Beta
0.752759
Previous close
$10.99
Today's open
$11
Day's range
$10.63 - $11.09
52 week range
$10.05 - $17.15
show more
CEO
Jay R. Luly
Employees
120
Headquarters
Watertown, MA
Exchange
Nasdaq Global Select
Shares outstanding
29125402
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2026. “During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients.
Business Wire • Nov 16, 2026

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.87 per share a year ago.
Zacks Investment Research • Nov 16, 2026

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences. 2026 Jefferies Global Healthcare Conference in London: Fireside Chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT / 9:30 a.m. EST 9th Annual Evercore Healthcare Conference: Fires.
Business Wire • Nov 4, 2026

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to serve as a Strategic Advisor for the remainder of 2027 to support a smooth and orderly tr.
Business Wire • Oct 28, 2026

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027. “We are excited to advance our zeli.
Business Wire • Oct 26, 2026

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center i.
Business Wire • Oct 13, 2026

Enanta Pharmaceuticals to Participate in September Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September: Baird 2026 Global Healthcare Conference: Fireside Chat on Tuesday, September 15, 2026 at 1:25 p.m. ET H.C. Wainwright 28th Annual Global Investment Conference: Fireside Chat on Wednesday,.
Business Wire • Sep 1, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. “Dosing began in LOTUS, our Phase.
Business Wire • Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.85 per share a year ago.
Zacks Investment Research • Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research • Jun 24, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Enanta Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.